75 results
8-K
EX-99.1
KROS
Keros Therapeutics Inc
6 Mar 24
March 2024 Corporate Presentation
8:01am
) Any treatment-related TEAE 33 (41.8) Any TESAE 28 (35.4) Any treatment-related TESAE 3 (3.8) Any TEAE leading to death 2 (2.5) Any TEAE leading to KER … in Exploratory Analysis ▸ In patients with LR-MDS, cardiovascular (CV) events represent a major cause of death possibly due to myocardial stress
424B5
KROS
Keros Therapeutics Inc
4 Jan 24
Prospectus supplement for primary offering
4:02pm
, as well as an increased risk of death. According to the World Health Organization, in 2016, more than 1.9 billon adults worldwide were overweight, with 650
424B5
KROS
Keros Therapeutics Inc
3 Jan 24
Prospectus supplement for primary offering
4:04pm
and some cancers, as well as an increased risk of death. According to the World Health Organization, in 2016, more than 1.9 billon adults worldwide
8-K
EX-99.1
wdhw0wls9b sis
3 Jan 24
January 2024 Corporate Presentation
8:04am
8-K
EX-99.2
xdb4aul17ii01zz
11 Dec 23
Keros Therapeutics Presents Clinical Data from its KER-050 Program at the 65th American Society of Hematology Annual Meeting and Exposition
6:02am
8-K
EX-99.1
hitab1ggbl3
6 Nov 23
November 2023 Corporate Presentation
8:11am
8-K
EX-99.1
nnrke1qbn4zsxlq2yl2j
7 Aug 23
August 2023 Corporate Presentation
4:02pm
8-K
EX-99.2
hre58m6v8b5dxrv ne3
9 Jun 23
Other Events
6:02am
8-K
EX-99.2
oa3e0o5c7u1ot b9
12 Dec 22
Other Events
10:01am
8-K
EX-99.1
zv14h
4 Aug 22
August 2022 Corporate Presentation
5:13pm
8-K
EX-99.1
wzt47r0ciahlefav08zh
10 Jun 22
Other Events
6:03am